Corcept Therapeutics Inc (CORT) Q1 2019 10-Q Quarterly Earnings

Short answer

Corcept Therapeutics Inc (CORT) filed its Q1 2019 10-Q quarterly report on May 9, 2019 for the quarter ended Mar 31, 2019.

AI summary of MD&A and risk factor updates

Revenue $64.8M, up from $57.7M YoY, driven by higher Korlym sales volume
Cost-of-sales margin 98.1% vs 98.0% YoY, with costs at 1.9% vs 2.0% of revenue
Best R&D performer: Endocrinology spending $6.8M vs $4.1M YoY
Cash, equivalents and securities $215.8M vs $206.7M at December 31, 2018
Operating cash flow $23.7M vs $34.4M YoY; stock repurchases $13.6M in Q1
2019 outlook: higher R&D and SG&A spending, operations funded without additional financing expected

Generic competition risk: Korlym’s orphan-drug exclusivity expired February 17, 2019, enabling generic challengers after FDA approval
Intellectual-property risk: Neptune’s IPR could invalidate claims of the ’348 patent, with oral argument set for November 14, 2019
Regulatory risk: GDPR noncompliance penalties reach €20 million or 4% of worldwide annual revenue, whichever is greater
Operational risk: Optime dispenses Korlym and collects approximately 99% of revenue from insurers and other payers
Liquidity risk: Revenue declines could require financing, potentially causing equity dilution or restrictive debt covenants

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.